AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06749678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period. It includes the following strategies: (1) Exercise: Exercise should be carried out when the patient's condition allows, and the exercise programme should be dynamically adjusted according to the patient's tolerance, and it is advisable to maintain the Borg score between 11\~13 points (i.e., subjectively feel relaxed or a little strained). (2) Nutritional support: ensure that the patient's daily energy intake is 20\~25kcal/kg (the target energy reaches 30\~35kcal/kg), and the protein intake is 1.2\~1.5g/(kg·d). (3) Psychological intervention: for patients with mild to moderate anxiety or depression, health education, music therapy and other psychological interventions are carried out. For patients with severe anxiety or depression, psychologists will conduct psychological consultation for patients and provide professional psychological therapy.
Study NCT04811313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive standard care but neither TXA nor caudal epidural block
Study NCT06749678 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine nursing measures
Description: Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
Study NCT06749678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine nursing measures
Description: Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
Study NCT04868864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
Study NCT05917249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacitive-Resistive Noninvasive Radiofrequency
Description: The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
Study NCT06494878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75-100 mg taken once daily by mouth.
Study NCT06494878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Study NCT04926194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual stromal cells (DSC)
Description: DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
Study NCT05566587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mediteranean to Western to Mediteranean Diet
Description: week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
Study NCT05566587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Western to Mediteranean to Western Diet
Description: week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
Study NCT04991974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
Study NCT04991974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
Study NCT04991974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community.
Study NCT05956691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AllerPops
Description: Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
Study NCT05956691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AllerPops
Description: Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
Study NCT06132464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanding Communication and Language Generated in Conversation Treatment
Description: ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
Study NCT06483087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated Education Program
Description: Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
Study NCT06236256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system
Description: The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
Study NCT06236256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MDI/CSII
Description: Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
Study NCT05679037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive capsules
Study NCT05679037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid 600 MG Oral Capsule
Description: Universal antioxidant
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 1
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 5ug of CM350 on the first day of first cycle (C1D1), 5ug on C1D8, 5ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05347498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR091506 tablets + placebo of febuxostat tablets
Description: HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
Study NCT05347498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablets + placebo of HR091506 tablets
Description: febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
Study NCT05569317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: primary nursing
Description: The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 2
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 15ug of CM350 on the first day of first cycle (C1D1), 15ug on C1D8, 15ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 3
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 45ug on C1D8, 45ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 4
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 5a
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 5b
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 6a
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 6b
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 7
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 8
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_MTD level
Description: CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05263960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_MTD-1 level
Description: CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05079269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: As above
Study NCT05032937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Description: Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Study NCT06345560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: 4 mg tablet once daily
Study NCT04814043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
Study NCT04465734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Study NCT04465734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
Study NCT04465734 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
Study NCT05685524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation test
Description: Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
Study NCT05154552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
Study NCT05154552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises
Study NCT05154552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises
Study NCT05044728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody combined with Paclitaxel and carboplatin.
Description: Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy.
Study NCT05044728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment stage
Description: After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
Study NCT04629599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for major depression following perinatal loss
Description: Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.